E 250
E 250 structure
|
Common Name | E 250 | ||
|---|---|---|---|---|
| CAS Number | 2079-54-1 | Molecular Weight | 223.74 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C13H18ClN | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
|
[Liver monoamine oxidase activity of the lamprey Lampetra fluviatilis. the substrate-inhibitory specificity].
Zh. Evol. Biokhim. Fiziol. 49(1) , 39-43, (2013) Based on data of substrate-inhibitory analysis with use of specific inhibitors--deprenyl, chlorgi-lin--and specific substrates--serotonin, noradrenalin, benzylamine, beta-phenylethylamine, and N-methylhistamine--a suggestion is put forward about the possible ... |
|
|
Bacopa monnieri and L-deprenyl differentially enhance the activities of antioxidant enzymes and the expression of tyrosine hydroxylase and nerve growth factor via ERK 1/2 and NF-κB pathways in the spleen of female wistar rats.
Neurochem. Res. 38(1) , 141-52, (2013) Aging is characterized by development of diseases and cancer due to loss of central and peripheral neuroendocrine-immune responses. Free radicals exert deleterious effects on neural-immune functions in the brain, heart, and lymphoid organs and thus, affecting... |
|
|
Selegiline (deprenyl) decreases calbindin-D28k expression in cortical neurons of rats socially deprived during the post-weaning period.
Int. J. Dev. Neurosci. 31(2) , 145-9, (2013) Preclinical studies indicate that selegiline (deprenyl), frequently used in some neurodegenerative diseases, exert protective effects on central nervous system neurons of individuals exposed to social isolation (SI). Furthermore, it has been suggested that SI... |
|
|
L-Deprenyl reverses age-associated decline in splenic norepinephrine, interleukin-2 and interferon-γ production in old female F344 rats.
Neuroimmunomodulation 20(2) , 72-8, (2013) Aging in female rats is associated with cessation of reproductive cycles, development of mammary cancer, and increased incidence of autoimmune diseases. Previously, we demonstrated an age-related decline in sympathetic noradrenergic (NA) innervation in the sp... |
|
|
Management of sexual dysfunction due to antipsychotic drug therapy.
Cochrane Database Syst. Rev. 11 , CD003546, (2012) Psychotropic drugs are associated with sexual dysfunction. Symptoms may concern penile erection, lubrication, orgasm, libido, retrograde ejaculation, sexual arousal, or overall sexual satisfaction. These are major aspects of tolerability and can highly affect... |
|
|
In vitro interactions of amantadine hydrochloride, R-(-)-deprenyl hydrochloride and valproic acid sodium salt with antifungal agents against filamentous fungal species causing central nervous system infection.
Acta Biol. Hung. 63(4) , 490-500, (2012) The mortality rates of fungal infections that affect the central nervous system are high in consequence of the absence of effective antifungal drugs with good penetration across the blood-brain barrier and the blood-cerebrospinal fluid barrier. In the present... |
|
|
Monoamine oxidase inhibitors revisited: what you should know.
J. Clin. Psychiatry 74(2) , 189-91, (2013)
|
|
|
4D-PET/CT with [(11)C]-PK11195 and [(11)C]-(D)-deprenyl does not identify the chronic inflammation in asymptomatic abdominal aortic aneurysms.
Eur. J. Vasc. Endovasc. Surg. 45(4) , 351-6, (2013) The aim of this study was to investigate the relevance of inflammation in the pathogenesis of abdominal aortic aneurysm (AAA) in vivo with two novel positron emission tomography (PET) tracers: [(11)C]-PK11195 which targets the translocator protein (18 kDa) ex... |
|
|
Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy.
Ir. Med. J. 106(1) , 24-5, (2013) Impulse control disorders (ICDs) are a known side effect of dopamine replacement therapy in patients with Parkinson's disease (PD). They can have devastating consequences for patients and their families. |
|
|
The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease.
Expert Opin. Drug Metab. Toxicol. 9(5) , 629-36, (2013) Parkinson's disease affects a growing number of people. Its major treatment, levodopa therapy, however suffers from response fluctuations in the advanced phase of the disease. Adjunctive therapies have thus gained significant importance. The selective monoami... |